CompletedInterventionalPhase 4Updated Oct 12, 2021
Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy | NCT03030300 | Trialant
CompletedInterventionalPhase 4Updated Jan 25, 2017
Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy
ClinicalTrials.gov ID
NCT03030300
Lead Sponsor
Qianfoshan HospitalOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
170Actual
Last Update Posted
Jan 25, 2017Estimated
Start Date
Jan 2008
Primary Completion Date
Feb 2015Actual
Completion Date
Feb 2015Actual
Brief Summary
To evaluate the long-term remission rate of short-term intensive insulin (STII) therapy in newly diagnosed type 2 diabetes outpatients and investigate the predictors contributing to the remission rate.
Type2 Diabetes
Novolin 30R;Pioglitazone;Metformin
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed, insulin-naive type 2 diabetes outpatients
Diabetes duration less than 1 year
Exclusion Criteria:
Various acute complications
Hepatic transaminase >2.5x normal reference value (glutamic-pyruvic transminase>100U/L, glutamic-oxalacetic transaminase > 100U/L)
Abnormal renal functions (serum cretinine>the normal reference value)
Cardiac insufficiency (America NYHA caediac function >3)